CoCites: A citation-based method for searching scientific literature

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson, Gabriela Plesa, Fang Chen, Megan M Davis, Wei-Ting Hwang, Regina M Young, Jennifer L Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L Siegel, Bruce L Levine, Carl H June, Michael C Milone. J Clin Invest 2019
Times Cited: 304

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, Zhubin J Gahvari, Elizabeth McGehee, Megan H Jagosky, Ridhi Gupta, William Varnado, Mark A Fiala, Saurabh Chhabra, Ehsan Malek, Joshua Mansour, Barry Paul, Alyssa Barnstead, Saranya Kodali, Amarendra Neppalli, Michaela Liedtke, Swapna Narayana, Kelly N Godby, Yubin Kang, Ankit Kansagra, Elvira Umyarova, Emma C Scott, Parameswaran Hari, Ravi Vij, Saad Z Usmani, Natalie S Callander, Shaji K Kumar, Luciano J Costa. Leukemia 2019
Times Cited: 182

List of shared articles

Times cited

Recommendations on the management of multiple myeloma in 2020.
Marie-Christiane Vekemans, Chantal Doyen, Jo Caers, Kalung Wu, Alain Kentos, Philippe Mineur, Lucienne Michaux, Michel Delforge, Nathalie Meuleman. Acta Clin Belg 2022

The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
Dawn Swan, David Routledge, Simon Harrison. Br J Haematol 2022

Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Arjun Lakshman, Shaji K Kumar. Am J Hematol 2022

Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Larry D Anderson. Future Oncol 2022

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.
José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso, Juan-José Lahuerta. Biomark Res 2022

Current state and next-generation CAR-T cells in multiple myeloma.
Salomon Manier, Tiziano Ingegnere, Guillaume Escure, Chloé Prodhomme, Morgane Nudel, Suman Mitra, Thierry Facon. Blood Rev 2022

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Ruiting Guo, Wenyi Lu, Yi Zhang, Xinping Cao, Xin Jin, Mingfeng Zhao. Front Immunol 2022

BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Barry Paul, Cesar Rodriguez, Saad Z Usmani. Drugs 2022

CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.
Juan Du, Runhong Wei, Songfu Jiang, Hua Jiang, Lu Li, Wanting Qiang, Haiyan He, Lin Shi, Qiuling Ma, Kang Yu,[...]. Am J Hematol 2022

BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.
Edmund Watson, Faouzi Djebbari, Alexandros Rampotas, Karthik Ramasamy. Expert Rev Hematol 2022

An update on novel multiple myeloma targets.
Massimo Offidani, Laura Corvatta, Sonia Morè, Maria Valentina Manieri, Attilio Olivieri. Expert Rev Hematol 2022

Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.
Andrew J Cowan, Sherilyn A Tuazon, Andrew J Portuguese, Damian J Green. Cancer J 2021

A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
Marc Braunstein, Jonathan Weltz, Faith Davies. Expert Rev Hematol 2021

A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Chunrui Li, Wenyue Cao, Yimei Que, Qiuxiang Wang, Yi Xiao, Chaojiang Gu, Di Wang, Jue Wang, Lijun Jiang, Hao Xu,[...]. Clin Transl Med 2021